search
Back to results

Dose-confirmatory Bridging Study in Total Knee Replacement

Primary Purpose

Venous Thromboembolism

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
Rivaroxaban (BAY59-7939)
Rivaroxaban (BAY59-7939)
Rivaroxaban (BAY59-7939)
Enoxaparin
Sponsored by
Bayer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Venous Thromboembolism focused on measuring venous thromboembolism, prevention, orthopaedic surgery

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female patients aged 20 years or above
  • Patients undergoing elective TKR (the first replacement of the applicable knee joint)
  • Patients' written informed consent to participation after receiving detailed verbal and written information on any study specific procedures in advance

Exclusion Criteria:

  • Planned, staged major orthopedic surgery within 3 months prior to elective TKR or during this study
  • History of clinically significant active bleeding (e.g. intracranial bleeding, gastrointestinal bleeding*), or high bleeding risk

    *: within 3 months prior to elective TKR for gastrointestinal bleeding

  • Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk
  • Severe impaired renal function (CLCR calculated by Cockcroft-Gault formula: <30 mL/min)
  • Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to contrast media)
  • Ongoing anticoagulant therapy (e.g. warfarin, heparins and Factor Xa inhibitors other than study medication) that cannot be stopped (in the opinion of the investigator/sub investigator)
  • Subjects for whom epidural catheters are expected to be left in for longer than 18 hours post-operatively
  • Planned intermittent pneumatic compression during treatment period.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Arm 1

Arm 2

Arm 3

Arm 4

Arm Description

Outcomes

Primary Outcome Measures

A composite endpoint of any deep vein thrombosis (proximal and/or distal), non-fatal pulmonary embolism and death from all causes
Treatment-emergent bleeding (major, non-major clinically relevant, other non-major)

Secondary Outcome Measures

deep vein thrombosis (total, proximal, distal)
symptomatic venous thromboembolism
major venous thromboembolism (proximal deep vein thromboembolism, pulmonary embolism or venous thromboembolism-related death)
symptomatic venous thromboembolism

Full Information

First Posted
September 20, 2010
Last Updated
January 17, 2017
Sponsor
Bayer
Collaborators
Janssen Scientific Affairs, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT01206972
Brief Title
Dose-confirmatory Bridging Study in Total Knee Replacement
Official Title
Randomized, Double-blind, Parallel-group, Active-controlled, Dose-confirmatory Bridging Study of Rivaroxaban (BAY59-7939) 5 to 10 mg Once-daily Regimen With a Reference Drug of Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
June 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bayer
Collaborators
Janssen Scientific Affairs, LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing elective total knee replacement (TKR) and to confirm the extrapolability of global data to Japanese patients by comparing with data from overseas phase III study (RECORD 3 - Study 11356) and phase II studies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Thromboembolism
Keywords
venous thromboembolism, prevention, orthopaedic surgery

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
302 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm 1
Arm Type
Experimental
Arm Title
Arm 2
Arm Type
Experimental
Arm Title
Arm 3
Arm Type
Experimental
Arm Title
Arm 4
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Rivaroxaban (BAY59-7939)
Intervention Description
daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
Intervention Type
Drug
Intervention Name(s)
Rivaroxaban (BAY59-7939)
Intervention Description
daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
Intervention Type
Drug
Intervention Name(s)
Rivaroxaban (BAY59-7939)
Intervention Description
daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
Intervention Type
Drug
Intervention Name(s)
Enoxaparin
Intervention Description
daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
Primary Outcome Measure Information:
Title
A composite endpoint of any deep vein thrombosis (proximal and/or distal), non-fatal pulmonary embolism and death from all causes
Time Frame
up to Day 13 (±2 days)
Title
Treatment-emergent bleeding (major, non-major clinically relevant, other non-major)
Time Frame
from the first intake of study medication to no later than 2 days after the last intake of study drug
Secondary Outcome Measure Information:
Title
deep vein thrombosis (total, proximal, distal)
Time Frame
up to Day 13 (±2 days)
Title
symptomatic venous thromboembolism
Time Frame
up to Day 13 (±2 days)
Title
major venous thromboembolism (proximal deep vein thromboembolism, pulmonary embolism or venous thromboembolism-related death)
Time Frame
up to Day 13 (±2 days)
Title
symptomatic venous thromboembolism
Time Frame
within 30 days after stop of treatment with study drug

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients aged 20 years or above Patients undergoing elective TKR (the first replacement of the applicable knee joint) Patients' written informed consent to participation after receiving detailed verbal and written information on any study specific procedures in advance Exclusion Criteria: Planned, staged major orthopedic surgery within 3 months prior to elective TKR or during this study History of clinically significant active bleeding (e.g. intracranial bleeding, gastrointestinal bleeding*), or high bleeding risk *: within 3 months prior to elective TKR for gastrointestinal bleeding Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk Severe impaired renal function (CLCR calculated by Cockcroft-Gault formula: <30 mL/min) Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to contrast media) Ongoing anticoagulant therapy (e.g. warfarin, heparins and Factor Xa inhibitors other than study medication) that cannot be stopped (in the opinion of the investigator/sub investigator) Subjects for whom epidural catheters are expected to be left in for longer than 18 hours post-operatively Planned intermittent pneumatic compression during treatment period.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bayer Study Director
Organizational Affiliation
Bayer
Official's Role
Study Director
Facility Information:
City
Nagoya
State/Province
Aichi
ZIP/Postal Code
455-8530
Country
Japan
City
Matsudo
State/Province
Chiba
ZIP/Postal Code
271-8511
Country
Japan
City
Matsuyama
State/Province
Ehime
ZIP/Postal Code
790-8524
Country
Japan
City
Kawanuma
State/Province
Fukushima
ZIP/Postal Code
969-6593
Country
Japan
City
Koriyama
State/Province
Fukushima
ZIP/Postal Code
963-8501
Country
Japan
City
Asahikawa
State/Province
Hokkaido
ZIP/Postal Code
078-8237
Country
Japan
City
Hakodate
State/Province
Hokkaido
ZIP/Postal Code
040-8611
Country
Japan
City
Sapporo
State/Province
Hokkaido
ZIP/Postal Code
060-8648
Country
Japan
City
Kakogawa
State/Province
Hyogo
ZIP/Postal Code
675-8545
Country
Japan
City
Kobe
State/Province
Hyogo
ZIP/Postal Code
657-0068
Country
Japan
City
Nishinomiya
State/Province
Hyogo
ZIP/Postal Code
663-8501
Country
Japan
City
Tsukuba
State/Province
Ibaraki
ZIP/Postal Code
305-0854
Country
Japan
City
Iida
State/Province
Nagano
ZIP/Postal Code
395-8505
Country
Japan
City
Sasebo
State/Province
Nagasaki
ZIP/Postal Code
857-8575
Country
Japan
City
Tomigusuku
State/Province
Okinawa
ZIP/Postal Code
901-0243
Country
Japan
City
Hirakata
State/Province
Osaka
ZIP/Postal Code
573-8511
Country
Japan
City
Izumisano
State/Province
Osaka
ZIP/Postal Code
598-8577
Country
Japan
City
Izumi
State/Province
Osaka
ZIP/Postal Code
594-0071
Country
Japan
City
Kishiwada
State/Province
Osaka
ZIP/Postal Code
596-8501
Country
Japan
City
Kishiwada
State/Province
Osaka
ZIP/Postal Code
596-8522
Country
Japan
City
Osakasayama
State/Province
Osaka
ZIP/Postal Code
589-8511
Country
Japan
City
Sakai
State/Province
Osaka
ZIP/Postal Code
599-8271
Country
Japan
City
Takatsuki
State/Province
Osaka
ZIP/Postal Code
569-1192
Country
Japan
City
Adachi
State/Province
Tokyo
ZIP/Postal Code
121-0064
Country
Japan
City
Nerima-ku
State/Province
Tokyo
ZIP/Postal Code
177-8521
Country
Japan
City
Fukuoka
ZIP/Postal Code
813-0017
Country
Japan
City
Fukuoka
ZIP/Postal Code
819-8551
Country
Japan
City
Kyoto
ZIP/Postal Code
602-8026
Country
Japan
City
Osaka
ZIP/Postal Code
530-0012
Country
Japan
City
Osaka
ZIP/Postal Code
558-8558
Country
Japan
City
Saga
ZIP/Postal Code
849-8501
Country
Japan
City
Saitama
ZIP/Postal Code
336-8522
Country
Japan
City
Toyama
ZIP/Postal Code
930-8550
Country
Japan

12. IPD Sharing Statement

Learn more about this trial

Dose-confirmatory Bridging Study in Total Knee Replacement

We'll reach out to this number within 24 hrs